Abstract Measles has re-emerged as a significant public health threat in Indonesia, signaling gaps in immunization coverage and systemic health inequities. Following the disruptions caused by the COVID-19 pandemic, the country has seen a troubling resurgence in cases. This editorial examines the current epidemiological situation, structural barriers to vaccination, and necessary strategies for elimination. In 2025, Indonesia recorded over 63,000 suspected cases, with the trend continuing into 2026. Current vaccination coverage for children aged 12–23 months stands at 73.46%, which is significantly below the 95% threshold required for herd immunity. Key barriers identified include maternal education levels, archipelagic geography, and sociocultural factors such as religious permissibility and safety concerns. Addressing the measles resurgence requires a multi-faceted approach: strengthening routine and catch-up immunization services, addressing social determinants of health, and rebuilding public trust through community engagement. Achieving high coverage is essential to prevent severe clinical complications and protect vulnerable populations.
Measles ; Measles resurgence ; Immunization coverage ; Indonesia ; Vaccine hesitancy ; Public health systems

Abstract The Nipah virus (NiV) is a highly pathogenic zoonotic virus associated with recurrent outbreaks in South and Southeast Asia. Since its first identification in 1998 among the pig farmers in Sungai Nipah Village in Malaysia, NiV has demonstrated high case fatality rates (40–75%) and significant epidemic potential. At that time, the virus spread to Singapore, and human cases were also identified in India, Bangladesh, and Philippine afterwards. No human cases have been reported in Indonesia; the country remains on high alert due to geographic concerns and the intensity of mobilization of people. To review the current global epidemiological situation of Nipah virus (as of 2026), evaluate public health preparedness, and analyze ongoing research efforts, including vaccine and therapeutic development.Nipah virus outbreaks remain geographically concentrated in Bangladesh and India, with seasonal spillover events linked primarily to bat-to-human transmission through contaminated food products. Human-to-human transmission occurs but remains limited. Improved surveillance, rapid case isolation, and contact tracing have reduced outbreak sizes in recent years. Vaccine candidates are currently in Phase II clinical trials.While the global pandemic risk remains low at present, the Nipah virus continues to represent a high-consequence emerging pathogen. Sustained surveillance, vaccine development, ecological research, and strengthened health systems are critical to mitigating future risks.
Nipah virus ; zoonotic diseases ; emerging infections ; encephalitis ; outbreak preparedness

Abstract Background: Dengue fever continues to spread worldwide, particularly in tropical regions. Some patients with dengue fever may progress to severe dengue, which is associated with significantly higher morbidity and mortality. Despite this, no definitive treatment has been found to prevent its progression. Montelukast, a leukotriene receptor antagonist, has shown potential in reducing plasma leakage, a key factor in the pathophysiology of severe dengue. Therefore, this study aimed to evaluate the effectiveness of montelukast in reducing the risk of severe dengue. Methods: A systematic literature search was conducted on April 16, 2025, using keywords related to montelukast and dengue across four databases, which included PubMed, Taylor and Francis, Cochrane Library, and ScienceDirect. A critical appraisal was performed using the Oxford Centre for Evidence-Based Medicine framework, evaluating the validity, importance, and applicability of each study. The primary outcomes were the incidence of dengue shock syndrome and dengue with warning signs. The secondary outcomes included mortality rate and hospitalization duration. Results: This study included three studies involving a total of 1057 patients. Montelukast is associated with a reduced incidence of dengue shock syndrome and shorter duration of hospitalization. However, the effect of montelukast on dengue with warning signs and mortality rate was inconclusive. Conclusion: Montelukast shows potential as an adjuvant therapy in preventing the progression of dengue fever to severe dengue. However, further research is required before montelukast can be widely recommended for dengue fever patients in daily clinical practice and possibly integrated into dengue fever clinical guidelines.
evidence-based case report ; severe dengue ; dengue fever ; leukotriene receptor antagonist ; montelukast